IRIS
BAGNASCO, DIEGO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 7.880
AS - Asia 1.229
NA - Nord America 1.116
Continente sconosciuto - Info sul continente non disponibili 244
SA - Sud America 98
AF - Africa 24
OC - Oceania 2
Totale 10.593
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 7.617
US - Stati Uniti d'America 1.043
SG - Singapore 420
CN - Cina 332
VN - Vietnam 219
BD - Bangladesh 134
FR - Francia 84
FI - Finlandia 55
BR - Brasile 53
HK - Hong Kong 43
CA - Canada 34
AR - Argentina 26
DE - Germania 23
RS - Serbia 23
NL - Olanda 16
MX - Messico 15
JP - Giappone 14
GB - Regno Unito 11
ID - Indonesia 11
IQ - Iraq 8
ES - Italia 7
IN - India 7
EC - Ecuador 6
IE - Irlanda 6
ZA - Sudafrica 5
AT - Austria 4
CH - Svizzera 4
MA - Marocco 4
NP - Nepal 4
PL - Polonia 4
RU - Federazione Russa 4
SA - Arabia Saudita 4
VE - Venezuela 4
AE - Emirati Arabi Uniti 3
AZ - Azerbaigian 3
BG - Bulgaria 3
CL - Cile 3
HN - Honduras 3
JO - Giordania 3
NI - Nicaragua 3
PE - Perù 3
PK - Pakistan 3
SN - Senegal 3
TH - Thailandia 3
TT - Trinidad e Tobago 3
UZ - Uzbekistan 3
AU - Australia 2
AW - Aruba 2
BE - Belgio 2
CR - Costa Rica 2
CY - Cipro 2
DO - Repubblica Dominicana 2
EG - Egitto 2
GT - Guatemala 2
JM - Giamaica 2
KE - Kenya 2
KZ - Kazakistan 2
MD - Moldavia 2
PH - Filippine 2
PR - Porto Rico 2
PT - Portogallo 2
PY - Paraguay 2
RO - Romania 2
SE - Svezia 2
TN - Tunisia 2
TR - Turchia 2
UA - Ucraina 2
BS - Bahamas 1
BW - Botswana 1
BY - Bielorussia 1
CO - Colombia 1
DK - Danimarca 1
DZ - Algeria 1
ET - Etiopia 1
GA - Gabon 1
GH - Ghana 1
GR - Grecia 1
KG - Kirghizistan 1
KR - Corea 1
LB - Libano 1
LT - Lituania 1
LV - Lettonia 1
MY - Malesia 1
OM - Oman 1
PS - Palestinian Territory 1
SC - Seychelles 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
SV - El Salvador 1
TW - Taiwan 1
VG - Isole Vergini Britanniche 1
Totale 10.349
Salva come PNG Salva come JPEG
Città #
Genoa 3.046
Genova 2.913
Vado Ligure 733
Rapallo 675
San Jose 263
Singapore 174
Ashburn 137
Ho Chi Minh City 68
Hanoi 63
Lauterbourg 60
Council Bluffs 58
New York 56
Helsinki 53
Beijing 52
Hong Kong 40
Bordighera 31
Santa Clara 23
Belgrade 22
Milan 22
Los Angeles 19
Frankfurt am Main 18
Rome 18
Naples 16
Haiphong 13
Tokyo 13
Chicago 12
Turin 12
Buffalo 11
Boardman 10
Bologna 10
Mexico City 9
Amsterdam 8
Da Nang 8
Atlanta 7
Miami 7
Orem 7
Tampa 7
Dublin 6
Shanghai 6
Toronto 6
Biên Hòa 5
Brooklyn 5
Columbus 5
Dallas 5
East Gwillimbury 5
Madrid 5
Montreal 5
Bergamo 4
Boston 4
Cagliari 4
Lancaster 4
Las Vegas 4
Ninh Bình 4
Orlando 4
The Bronx 4
Tianjin 4
Trieste 4
Verona 4
Alexandria 3
Baku 3
City of London 3
Cleveland 3
Dakar 3
Dayton 3
Denver 3
Houston 3
Hải Dương 3
Jakarta 3
Lima 3
London 3
Managua 3
Milton 3
Newark 3
North Bergen 3
Paris 3
Phoenix 3
Piscataway 3
San Antonio 3
San Francisco 3
Tashkent 3
Villa San Giovanni 3
Vĩnh Long 3
Zurich 3
Alpharetta 2
Angri 2
Aurora 2
Bangkok 2
Bari 2
Birmingham 2
Brescia 2
Brussels 2
Bushnell 2
Cairo 2
Can Tho 2
Cape Town 2
Cardiff 2
Cedar Rapids 2
Certaldo 2
Chaguanas 2
Córdoba 2
Totale 8.900
Salva come PNG Salva come JPEG
Nome #
Clinical characteristics, management and in-hospital mortality of patients with COVID-19 In Genoa, Italy 345
Personalized medicine in allergy 214
A critical evaluation of Anti-IL-13 and Anti-IL-4 strategies in severe asthma 209
Molecular phenotyping and biomarker development: Are we on our way towards targeted therapy for severe asthma? 202
Anti-Interleukin 5 (IL-5) and IL-5Ra Biological Drugs: Efficacy, Safety, and Future Perspectives in Severe Eosinophilic Asthma 198
Anti-IL-5 and IL-5Ra: Efficacy and safety of new therapeutic strategies in severe uncontrolled asthma 197
Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life 196
Prevalence and prognostic value of cardiac troponin in elderly patients hospitalized for COVID-19 193
Mepolizumab in the management of severe eosinophilic asthma in adults: Current evidence and practical experience 191
Analysis of the drop-out rate in patients receiving mepolizumab for severe asthma in real life 186
Sleep complaints and sleep breathing disorders in upper and lower obstructive lung diseases 179
ARIA-ITALY multidisciplinary consensus on nasal polyposis and biological treatments 178
Current insights in allergen immunotherapy 176
Clinical characteristics, management and in-hospital mortality of patients with coronavirus disease 2019 in Genoa, Italy 172
30 Years Of Sublingual Immunotherapy 171
Impact of tDCS on persistent COVID-19 olfactory dysfunction: a double-blind sham-controlled study 170
When to stop biologicals. Severe asthma exacerbation after mepolizumab discontinuation 168
Targeting Interleukin-5 or Interleukin-5Rα: Safety Considerations 167
Umeclidinium for the treatment of uncontrolled asthma 166
Biosimilars in allergic diseases 165
Mepolizumab in severe asthma: evidence in real-life 164
The safety of monoclonal antibodies in asthma 161
Benefit of SLIT and SCIT for Allergic Rhinitis and Asthma 160
MK-8237: a house dust mite vaccine for treating allergic rhinitis, asthma and atopic dermatitis 160
Efficacy of mepolizumab in patients with previous omalizumab treatment failure: Real-life observation 157
The path to personalized medicine in asthma 156
Extensive activation, tissue trafficking, turnover and functional impairment of NK cells in COVID-19 patients at disease onset associates with subsequent disease severity 148
Update on immunotherapy for the treatment of asthma 145
Dupilumab Effectiveness in Patients with Severe Allergic Asthma Non-Responsive to Omalizumab 144
Severe asthma, biologicals, and auto-injection: Yes, no, may be! 140
Pharmacokinetics and pharmacodynamics of monoclonal antibodies for asthma treatment 134
Adherence to Allergen Subcutaneous Immunotherapy is Increased by a Shortened Build-Up Phase: A Retrospective Study 134
Reslizumab and Eosinophilic Asthma: One Step Closer to Precision Medicine? 131
Multiple pulmonary nodules and unexplained fever: when the pulmonologist fails. 127
The North-Western Italian experience with anti IL-5 therapy amd comparison with regulatory trials 126
Biologicals for severe asthma: what we can learn from real-life experiences? 124
The importance of being not significant: blood eosinophils and clinical responses do not correlate in severe asthma patients treated with Mepolizumab in real life 124
One year of mepolizumab. Efficacy and safety in real-life in Italy 123
Cerebrospinal Fluid Leak Repair: Usefulness of Intrathecal Fluorescein for Correct Topographic Identification of the Skull Base Defects 122
IL-13 and idiopathic pulmonary fibrosis: Possible links and new therapeutic strategies 110
Anti-il5 therapies for severe eosinophilic asthma: Literature review and practical insights 110
Long-Term Efficacy of Mepolizumab at 3 Years in Patients with Severe Asthma: Comparison with Clinical Trials and Super Responders 109
Efficacy and safety of honeybee and wasp tyrosine-adsorbed venom immunotherapy 109
Quick Olfactory Sniffin’ Sticks Test (Q-Sticks) for the detection of smell disorders in COVID-19 patients 108
Kidney disease and all-cause mortality in patients with COVID-19 hospitalized in Genoa, Northern Italy 105
Application of bioendoscopy filters in endoscopic assessment of sinonasal Schneiderian papillomas 104
Personalized and Precision Medicine in Asthma and Eosinophilic Esophagitis: The Role of T2 Target Therapy 104
Minimal clinically important difference for asthma endpoints: An expert consensus report 103
Asthma in a large COVID-19 cohort: Prevalence, features, and determinants of COVID-19 disease severity 102
Biologics in Severe Eosinophilic Asthma: Three-Year Follow-Up in a SANI Single Center 97
Interleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders: evidence and unmet needs 95
Biological agents for severe asthma: the evolution of the at-home self-injection approach. 94
FEV6 assessment in spirometric abnormalities screening: the first population-based study in Italian pharmacies 88
Evolving phenotypes to endotypes: is precision medicine achievable in asthma? 87
A case of chronic eosinophilic pneumonia in a patient treated with dupilumab 86
Severe asthma: One disease and multiple definitions 84
Severe chronic rhinosinusitis treated with dupilumab, a real-life analysis of early effectiveness 82
Tralokinumab as an Alternative to Dupilumab in a Patient with Atopic Dermatitis and Asthma who Developed Hypereosinophilia: A Case Report 82
Diagnostic therapeutic assistance pathway (PDTA) of type 2 chronic rhinosinusitis 81
Omalizumab and cancer risk: Current evidence in allergic asthma, chronic urticaria, and chronic rhinosinusitis with nasal polyps 80
Epithelial dysfunction, respiratory infections and asthma: the importance of immunomodulation. A focus on OM-85 74
Severe Asthma Network Italy Definition of Clinical Remission in Severe Asthma: A Delphi Consensus 71
Impulse oscillometry defined small airway dysfunction in asthmatic patients with normal spirometry: Prevalence, clinical associations, and impact on asthma control 71
Thymic Stromal Lymphopoietin and Tezepelumab in Airway Diseases: From Physiological Role to Target Therapy 70
Nasal cytology as a reliable non-invasive procedure to phenotype patients with type 2 chronic rhinosinusitis with nasal polyps 68
Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI) 68
Specific Therapy for T2 Asthma 65
Aspergillus-related diseases in a cohort of patients with severe asthma: A SANI single-center report 64
Significant improvement in lung function and asthma control after benralizumab treatment for severe refractory eosinophilic asthma 62
Do the current guidelines for asthma pharmacotherapy encourage over-treatment? 59
COVID-19 in severe asthmatic patients during ongoing treatment with biologicals targeting type 2 inflammation: Results from a multicenter Italian survey 59
Background therapy in severe asthma on monoclonal antibody treatment in real life 58
Effectiveness and safety of dupilumab in patients with chronic rhinosinusitis with nasal polyps and associated comorbidities: a multicentric prospective study in real life 57
Real-life studies of biologics used in asthma patients: key differences and similarities to trials 57
Personalizing the approach to asthma treatment 57
SANI clinical remission definition: a useful tool in severe asthma management 55
COPD, but Not Asthma, Is Associated with Worse Outcomes in COVID-19: Real-Life Data from Four Main Centers in Northwest Italy 55
Unlocking the Long-Term Effectiveness of Benralizumab in Severe Eosinophilic Asthma: A Three-Year Real-Life Study 55
Biologics and Bronchial Thermoplasty for severe refractory asthma treatment: From eligibility criteria to real practice. A cross-sectional study 55
null 49
Management of Patients with Severe Asthma and Chronic Rhinosinusitis with Nasal Polyps: A Multidisciplinary Shared Approach 49
Different aspects of severe asthma in real life: Role of Staphylococcus aureus enterotoxins and correlation to comorbidities and disease severity 47
Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): Focus on the Pathophysiological and Diagnostic Role of Viruses 47
Prospective Italian real-world study of mepolizumab in severe eosinophilic asthma validates retrospective outcome reports 46
Biologics for the Treatments of Allergic Conditions: Severe Asthma 46
Benralizumab Efficacy in Late Non-Responders to Mepolizumab and Variables Associated with Occurrence of Switching: A Real-Word Perspective 44
Real-life studies in allergen immunotherapy 44
Strategies to reduce corticosteroid-related adverse events in asthma 41
New suggestions in sublingual immunotherapy for house dust mite-related allergic diseases 40
New suggestions in sublingual immunotherapy for house dust mite-related allergic diseases 38
Efficacy and steroid-sparing effect of benralizumab: Has it an advantage over its competitors? 37
Type 2 immunity in asthma 34
Small Airways: The “Silent Zone” of 2021 GINA Report? 29
Comparing a fixed combination of budesonide/formoterol with other inhaled corticosteroid plus long-acting beta-agonist combinations in patients with chronic obstructive pulmonary disease: a review 28
Reduction of oral corticosteroids in patients with severe eosinophilic asthma treated with Benralizumab: could it represent a marker of treatment efficacy? 27
The new indications for biologicals in type 2 diseases: perspectives 26
Strategies to reduce corticosteroid-related adverse events in asthma 21
Personalized medicine and allergen immunotherapy: the beginning of a new era? 20
COVID-19, Eosinophils, and Biologicals for Severe Asthma 19
Mepolizumab in Patients With Severe Asthma and Comorbidities: 1-Year REALITI-A Analysis 17
Totale 10.472
Salva come PNG Salva come JPEG
Categoria #
all - tutte 39.548
article - articoli 39.154
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 78.702
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022584 19 11 17 63 14 71 23 128 53 73 14 98
2022/2023814 66 74 6 67 86 126 53 37 141 53 90 15
2023/2024701 42 81 9 79 48 177 41 42 35 13 46 88
2024/20251.966 56 133 58 137 215 214 157 302 100 98 257 239
2025/20263.731 496 129 293 208 464 254 504 181 326 295 278 303
2026/2027312 312 0 0 0 0 0 0 0 0 0 0 0
Totale 10.593